Seuraa
Jelle Wesseling
Jelle Wesseling
Group Leader, Netherlands Cancer Institute
Vahvistettu sähköpostiosoite verkkotunnuksessa nki.nl - Kotisivu
Nimike
Viittaukset
Viittaukset
Vuosi
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 …
FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ...
PLoS medicine 7 (5), e1000279, 2010
12992010
Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma
C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ...
Nature 508 (7494), 118-122, 2014
9442014
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.
J Wesseling, SW van der Valk, HL Vos, A Sonnenberg, J Hilkens
The Journal of cell biology 129 (1), 255-265, 1995
5471995
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.
J Wesseling, SW van der Valk, J Hilkens
Molecular biology of the cell 7 (4), 565-577, 1996
4841996
Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure
M Donker, ME Straver, J Wesseling, CE Loo, M Schot, CA Drukker, ...
Annals of surgery 261 (2), 378-382, 2015
4792015
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ...
Nature genetics 49 (12), 1767-1778, 2017
4212017
Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy
M Jalving, JJ Koornstra, J Wesseling, HM Boezen, S De Jong, ...
Alimentary pharmacology & therapeutics 24 (9), 1341-1348, 2006
3892006
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk …
LE Elshof, K Tryfonidis, L Slaets, AE van Leeuwen-Stok, VP Skinner, N Dif, ...
European journal of cancer 51 (12), 1497-1510, 2015
3872015
Personalized early detection and prevention of breast cancer: ENVISION consensus statement
N Pashayan, AC Antoniou, U Ivanus, LJ Esserman, DF Easton, D French, ...
Nature reviews Clinical oncology 17 (11), 687-705, 2020
3822020
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised …
MS van Ramshorst, A van der Voort, ED van Werkhoven, IA Mandjes, ...
The Lancet Oncology 19 (12), 1630-1640, 2018
3672018
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types
S Jones, M Li, DW Parsons, X Zhang, J Wesseling, P Kristel, MK Schmidt, ...
Human mutation 33 (1), 100-103, 2012
3632012
Ductal carcinoma in situ: to treat or not to treat, that is the question
M van Seijen, EH Lips, AM Thompson, S Nik-Zainal, A Futreal, ES Hwang, ...
British journal of cancer 121 (4), 285-292, 2019
3462019
Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ...
The lancet oncology 8 (12), 1079-1087, 2007
3442007
Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype
CE Loo, ME Straver, S Rodenhuis, SH Muller, J Wesseling, ...
Journal of Clinical Oncology 29 (6), 660-666, 2011
3402011
The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
ME Straver, AM Glas, J Hannemann, J Wesseling, MJ van de Vijver, ...
Breast cancer research and treatment 119, 551-558, 2010
3402010
Tissue distribution of the death ligand TRAIL and its receptors
DC Spierings, EG de Vries, E Vellenga, FA van den Heuvel, JJ Koornstra, ...
Journal of Histochemistry & Cytochemistry 52 (6), 821-831, 2004
3322004
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ...
The Lancet Oncology 23 (1), 149-160, 2022
3282022
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ...
International journal of cancer 133 (4), 929-936, 2013
3012013
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
EH Lips, L Mulder, A Oonk, LE Van Der Kolk, FBL Hogervorst, ALT Imholz, ...
British journal of cancer 108 (10), 2172-2177, 2013
2862013
Receptor conversion in distant breast cancer metastases
LDC Hoefnagel, MJ van de Vijver, HJ Van Slooten, P Wesseling, ...
Breast cancer research 12, 1-9, 2010
2722010
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20